Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.

[1]  P. Tsirigotis,et al.  Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine‐based preparative regimen , 2006, British journal of haematology.

[2]  N. Geller,et al.  Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation , 2006, British journal of haematology.

[3]  H. Schrezenmeier,et al.  Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia , 2006, Bone Marrow Transplantation.

[4]  F. Locatelli,et al.  Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party , 2005, Bone Marrow Transplantation.

[5]  R. Krance,et al.  Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) , 2005, Bone Marrow Transplantation.

[6]  R. Krance,et al.  Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab , 2005, Bone Marrow Transplantation.

[7]  J. Passweg,et al.  Immunosuppression with ALG and CsA is first line treatment in children with SAA lacking an HLA identical sibling , 2005, Pediatric blood & cancer.

[8]  Y. Lee,et al.  Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia , 2005, Bone Marrow Transplantation.

[9]  S. Ball,et al.  Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning , 2005, Bone Marrow Transplantation.

[10]  G. Hale,et al.  Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  R. Krance,et al.  Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.

[12]  R. Porcher,et al.  Long-term outcome after bone marrow transplantation for severe aplastic anemia. , 2004, Blood.

[13]  Raymond J Carroll,et al.  A Reanalysis of Thyroid Neoplasms in the Israeli Tinea Capitis Study Accounting for Dose Uncertainties , 2004, Radiation research.

[14]  F. Locatelli,et al.  Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. , 2004, Haematologica.

[15]  H. Heimpel,et al.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. , 2003, Blood.

[16]  C. Craddock,et al.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.

[17]  G. Vassiliou,et al.  Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low‐dose total body irradiation, cyclophosphamide and Campath , 2001, British journal of haematology.

[18]  G. Hale,et al.  The CD52 antigen and development of the CAMPATH antibodies. , 2001, Cytotherapy.

[19]  G. Morgan,et al.  In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. , 2001, Cytotherapy.

[20]  S. Mackinnon,et al.  CAMPATH-1 antibodies in stem-cell transplantation. , 2001, Cytotherapy.

[21]  R. Collins,et al.  Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  H. Deeg,et al.  Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  T. Barbui,et al.  Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Tra , 2000, Blood.

[24]  J. Passweg,et al.  Current Results of Bone Marrow Transplantation in Patients with Acquired Severe Aplastic Anemia , 2000, Acta Haematologica.

[25]  D. Margolis,et al.  Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. , 2000, Seminars in hematology.

[26]  R. Collins,et al.  Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  J. V. Stone,et al.  Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .

[28]  J. Marsh,et al.  Treatment options in severe aplastic anaemia , 1998, The Lancet.

[29]  R. Storb,et al.  Primary Treatment of Acquired Aplastic Anemia: Outcomes with Bone Marrow Transplantation and Immunosuppressive Therapy , 1997, Annals of Internal Medicine.

[30]  H. Deeg,et al.  Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. , 1996, Transplantation.

[31]  H. Deeg,et al.  Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. , 1996, Blood.

[32]  N. Young,et al.  The treatment of severe acquired aplastic anemia. , 1995, Blood.

[33]  H. Deeg,et al.  Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. , 1994, Blood.

[34]  A. Gratwohl,et al.  Late clonal complications in severe aplastic anemia. , 1994, Leukemia & lymphoma.

[35]  A. Rimm,et al.  Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. , 1992, Blood.

[36]  M. Horowitz,et al.  IBMTR analysis of bone marrow transplants in acute leukaemia. Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR). , 1989, Bone marrow transplantation.

[37]  A. Gratwohl,et al.  Late haematological complications in severe aplastic anaemia , 1988, British journal of haematology.

[38]  Apperley,et al.  Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. , 1986, Blood.

[39]  D. Nathan,et al.  Selection of patients for bone marrow transplantation in severe aplastic anemia. , 1975, Blood.